既往降糖药物使用与64,892例糖尿病合并COVID-19退伍军人30天结局
该研究纳入64,892例糖尿病合并COVID-19的退伍军人,分析感染前HbA1c及降糖药物使用与30天住院、ICU入住和死亡的关系。结果显示HbA1c≥9.0%和胰岛素使用与不良结局直接相关,而GLP1-RA、二甲双胍和SGLT2i使用与较低风险相关。
要点
- HbA1c≥9.0%与30天住院、ICU入住和死亡风险升高相关。
- 胰岛素使用与30天住院、ICU入住和死亡风险升高相关。
- GLP1-RA、二甲双胍和SGLT2i使用与较低住院或死亡风险相关。
核心结论
- 在糖尿病合并COVID-19退伍军人中,较高HbA1c和胰岛素使用与不良结局直接相关,而GLP1-RA、二甲双胍和SGLT2i使用呈反向关联。
研究设计与样本
- 研究纳入64,892例糖尿病合并COVID-19的退伍军人,分析感染前HbA1c和降糖药物使用与30天结局的关联。
主要发现
- 与HbA1c<7.0%相比,HbA1c≥9.0%与30天住院OR 1.27(95%CI 1.19-1.35)、ICU入住OR 1.28(95%CI 1.15-1.42)、死亡OR 1.30(95%CI 1.17-1.44)相关。
- HbA1c≥9.0%与4.4个月随访期间死亡风险HR 1.22(95%CI 1.12-1.32)相关。
- 胰岛素使用与30天住院OR 1.12(95%CI 1.07-1.18)、ICU入住OR 1.12(95%CI 1.04-1.22)、死亡OR 1.18(95%CI 1.09-1.27)及死亡HR 1.12(95%CI 1.07-1.18)相关。
- SGLT2i、GLP1-RA或ARB使用与较低住院 odds 相关,OR分别为0.92(95%CI 0.85-0.99)、0.88(95%CI 0.81-0.96)、0.94(95%CI 0.89-0.99)。
- 二甲双胍和SGLT2i使用与较低死亡 odds 相关,OR分别为0.84(95%CI 0.78-0.91)、0.82(95%CI 0.72-0.94),死亡HR分别为0.84(95%CI 0.79-0.89)、0.82(95%CI 0.74-0.92)。
临床怎么用
- 对于糖尿病合并COVID-19患者,应关注感染前血糖控制水平,HbA1c≥9.0%提示不良结局风险增高。
- 感染前使用胰岛素可能与不良结局风险升高相关,需结合临床评估。
- 感染前使用GLP1-RA、二甲双胍或SGLT2i可能与较低不良结局风险相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify preinfection risk factors for adverse outcomes among veterans with diabetes and coronavirus disease 2019 (COVID-19) infection. RESEARCH DESIGN AND METHODS: We identified all Veterans Health Administration patients with diabetes and one or more positive nasal swab(s) for severe acute respiratory syndrome coronavirus 2 (1 March 2020-10 March 2021) (n = 64,892). We examined associations of HbA1c and glucose-lowering medication use with hospitalization, intensive care unit (ICU) admission, and mortality at 30 days using logistic regression models and during 4.4 months of follow-up (range <1-13.1) using proportional hazards models. RESULTS: Compared with HbA1c <7.0%, HbA1c ≥9.0% was associated with higher odds of hospitalization, ICU admission, and death at 30 days (odds ratio [OR] 1.27 [95% CI 1.19-1.35], 1.28 [95% CI 1.15-1.42], 1.30 [95% CI 1.17-1.44], respectively) as well as higher risk of death over 4.4 months (hazard ratio [HR] 1.22 [95% CI 1.12-1.32]). Insulin use was associated with higher odds of hospitalization, ICU admission, and death (OR 1.12 [95% CI 1.07-1.18], 1.12 [95% CI 1.04-1.22], and 1.18 [95% CI 1.09-1.27], respectively) and higher risk of death (HR 1.12 [95% CI 1.07-1.18]). Sodium-glucose cotransporter 2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonist (GLP1-RA), or angiotensin receptor blocker use were associated with lower odds of hospitalization (OR 0.92 [95% CI 0.85-0.99], 0.88 [95% CI 0.81-0.96], and 0.94 [95% CI 0.89-0.99], respectively). Metformin and SGLT2i use were associated with lower odds (OR 0.84 [95% CI 0.78-0.91], 0.82 [95% CI 0.72-0.94], respectively) and risk of death (HR 0.84 [95% CI 0.79-0.89], 0.82 [95% CI 0.74-0.92], respectively). CONCLUSIONS: Among veterans with diabetes and COVID-19, higher HbA1c and insulin use were directly associated with adverse outcomes, while use of a GLP1-RA, metformin, and SGLT2i was inversely associated.
引用
- Wander PL, Lowy E, Beste LA, et al. Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19. Diabetes Care. 2021. PMID: 34615690. doi:10.2337/dc21-1351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。